Table 1

Demographic and clinical characteristics of patients with severe FV deficiency

PatientSexAge, yFV level, %Coinherited thrombophilic defectsClinical phenotype*
PD I 64 < 0.5  Moderate/severe (5) 
PD II 44 < 0.5 170% FVIII Severe (7) 
PD III 35 0.6 131% PT (no F2 G20210A) Asymptomatic (0
PD IV 27 < 0.5  Mild (2) 
PD V 52 < 0.5  Severe (10
PD VI 28 < 0.5  Mild (1
PD VII 62 4.8  Mild (1) 
PD VII-A 46 6.2  Mild (1) 
GK 502 57 < 0.5  Mild 
GK 505 56 < 0.5 53% PC Unknown 
GK 506 65 < 0.5  Unknown 
PatientSexAge, yFV level, %Coinherited thrombophilic defectsClinical phenotype*
PD I 64 < 0.5  Moderate/severe (5) 
PD II 44 < 0.5 170% FVIII Severe (7) 
PD III 35 0.6 131% PT (no F2 G20210A) Asymptomatic (0
PD IV 27 < 0.5  Mild (2) 
PD V 52 < 0.5  Severe (10
PD VI 28 < 0.5  Mild (1
PD VII 62 4.8  Mild (1) 
PD VII-A 46 6.2  Mild (1) 
GK 502 57 < 0.5  Mild 
GK 505 56 < 0.5 53% PC Unknown 
GK 506 65 < 0.5  Unknown 

PT indicates prothrombin; and PC, protein C.

*

Numbers in parentheses represent the bleeding score calculated according to Rodeghiero et al.29 

Prophylaxis (with plasma and/or antifibrinolytic agents) often given during risk situations after the diagnosis of severe FV deficiency was made.

Close Modal

or Create an Account

Close Modal
Close Modal